Abstract:Background Immunotherapy for hepatocellular carcinoma (HCC) exhibits limited clinical efficacy due to immunosuppressive tumor microenvironment (TME). Tumor-infiltrating macrophages (TIMs) account for the major component in the TME, and the dominance of M2 phenotype over M1 phenotype in the TIMs plays the pivotal role in sustaining the immunosuppressive character. We thus investigate the effect of bufalin on promoting TIMs polarization toward M1 phenotype to improve HCC immunotherapy. Methods The impact of bufalin on evoking antitumor immune response was evaluated in the immunocompetent mouse HCC model. The expression profiling of macrophage-associated genes, surface markers and cytokines on bufalin treatment in vitro and in vivo were detected using flow cytometry, immunofluorescence, western blot analysis, ELISA and RT-qPCR. Cell signaling involved in M1 macrophage polarization was identified via the analysis of gene sequencing, and bufalin-governed target was explored by immunoprecipitation, western blot analysis and gain-and-loss of antitumor immune response. The combination of bufalin and antiprogrammed cell death protein 1 (anti-PD-1) antibody was also assessed in orthotopic HCC mouse model. Results In this study, we showed that bufalin can function as an antitumor immune modulator that governs the polarization of TIMs from tumor-promoting M2 toward tumor-inhibitory M1, which induces HCC suppression through the activation of effector T cell immune response. Mechanistically, bufalin inhibits overexpression of p50 nuclear factor kappa B (NF-κB) factor, leading to the predominance of p65-p50 heterodimers over p50 homodimers in the nuclei. The accumulation of p65-p50 heterodimers activates NF-κB signaling, which is responsible for the production of immunostimulatory cytokines, thus resulting in the activation of antitumor T cell immune response. Moreover, bufalin enhances the antitumor activity of anti-PD-1 antibody, and the combination exerts synergistic effect on HCC suppression. Conclusions These data expound a novel antitumor mechanism of bufalin, and facilitate exploitation of a new potential macrophage-based HCC immunotherapeutic modality.

Na+/K+-Atpase Alpha 3 Mediates Sensitivity Of Hepatocellular Carcinoma Cells To Bufalin

Bufalin attenuates the stage and metastatic potential of hepatocellular carcinoma in nude mice

Bufalin, a component in Chansu, inhibits proliferation and invasion of hepatocellular carcinoma cells

Bufalin Inhibits Htert Expression and Colorectal Cancer Cell Growth by Targeting CPSF4

Bufalin Inhibits Tumorigenesis and SREBP-1-Mediated Lipogenesis in Hepatocellular Carcinoma Via Modulating the ATP1A1/CA2 Axis

Global Metabolomic and Lipidomic Analysis Reveal the Synergistic Effect of Bufalin in Combination with Cinobufagin Against HepG2 Cells.

Bufalin Suppresses Hepatocellular Carcinoma Invasion and Metastasis by Targeting HIF-1α Via the PI3K/AKT/mTOR Pathway.

Bufalin Enhances the Anti-Proliferative Effect of Sorafenib on Human Hepatocellular Carcinoma Cells Through Downregulation of ERK

Bufalin Enhances Anti-Angiogenic Effect of Sorafenib Via AKT/VEGF Signaling.

The Research Progress of Bufalin in the Treatment of Hepatocellular Carcinoma

Bufalin suppresses hepatocellular carcinogenesis by targeting M2 macrophage-governed Wnt1/β-catenin signaling

PI3K/Akt is Involved in Bufalin-Induced Apoptosis in Gastric Cancer Cells

Synergistic Anticancer Effects of Bufalin and Sorafenib by Regulating Apoptosis Associated Proteins.

Synergistic Anti-Hepatoma Effect of Bufalin Combined with Sorafenib Via Mediating the Tumor Vascular Microenvironment by Targeting Mtor/vegf Signaling

Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma

Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin

Bufalin induces apoptosis and autophagy via the Ca2+/CaMKKβ/AMPK/Beclin1 signaling pathway in osteosarcoma cells

Bufalin targeting BFAR inhibits the occurrence and metastasis of gastric cancer through PI3K/AKT/mTOR signal pathway

[Anticancer Effect of SN-38 Combined with Sorafenib on Hepatocellular Carcinoma in Vitro and Its Mechanism].

Bufalin enhances the antitumor effect of gemcitabine in pancreatic cancer.

CBL0137 Administration Suppresses Human Hepatocellular Carcinoma Cells Proliferation and Induces Apoptosis Associated with Multiple Cell Death Related Proteins.